References
- Zandberg DP, Hendrick F, Vannorsdall E, et al. Tertiary center referral patterns for myelodysplastic syndrome patients are indicative of age and race disparities: a single-institution experience. Leuk Lymphoma 2013;54:304–309.
- Magalhães SMM, Madeira TS, Bittencourt R, et al. Epidemiological and clinicopathological data from the Brazilian registry of patients with myelodysplastic syndromes and comparative analysis between different geographic areas. Blood 2010;116(Suppl. 1): Abstract 1884.
- Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005;106:2633–2640.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2098.
- Mittelman M, Oster HS, Hoffman M, et al. The lower risk MDS patient at risk of rapid progression. Leuk Res 2010;34:1551–1555.
- Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536–1542.
- Neukirchen J, Schoonen WM, Strupp C et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 2011;35:1591–1596.
- Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90: 1168–1178.
- Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005;106:2633–2640.
- Lee JJ, Kim HJ, Chung IJ, et al. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 1999;23:425–432.
- Gologan R, Georgescu D, Tatic A, et al. Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res 2009;33:1556–1561.
- Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–4395.
- Heredia F, Sousa J, Magalhães SMM, et al. Therapy-related myelodysplastic syndrome with 17p deletion following long-term azathioprine treatment. Leuk Res 2010;34:e311–e312.
- Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433–1440.